Xenetic researches, develops and manufactures biopharmaceuticals: protein-based drugs for the treatment of human and veterinary diseases.
Please go to our Directors page to see the full list of directors
Xenetic was admitted to AIM (originally as Lipoxen plc) on 17th January 2006
As a public company, we report our results twice a year and these dates will be published in advance on our website
There are electronic versions of all the Company's financial reports in the Investor Centre section of the website. Hard copies can be obtained on request.